Series of national teleconferences featuring leading fertility health experts
to kick off Fertility LifeLines(TM), a new educational toll-free service
ROCKLAND, Mass., April 23 /PRNewswire/ -- Serono, Inc., a leader in
reproductive health, announced a series of national teleconferences to mark
the launch of Fertility LifeLines(TM), a free educational service that offers
customized information and support to people with fertility health concerns,
including the estimated 6 million Americans who suffer from infertility.
During the teleconferences, a group of nationally recognized experts will
offer practical tips for dealing with infertility and answers to pre-submitted
caller questions. Moderated by the American Infertility Association, the
teleconferences will take place nightly from May 10 to 12. Registration is
available now through May 9 by calling Fertility LifeLines(TM) toll-free at 1-
866-LETS-TRY (1-866-538-7879).
"About half of the women with impaired fertility don't seek the treatment
they need," says Pam Madsen, Executive Director of the American Infertility
Association. "We know from our research that many women avoid treatment
because they're afraid of disappointment. These teleconferences are a unique
opportunity to address people's concerns by talking openly about the issues in
a comfortable and convenient way." About 70% of patients who are treated for
infertility succeed in having children.
Each teleconference will take place from 8:00 pm to 9:00 pm EST:
-- Monday, May 10 - Infertility Treatment: Getting Your Questions
Answered, presented by fertility specialist Richard Scott, MD, Medical
Director, Reproductive Medicine Associates of New Jersey (RMA NJ)
-- Tuesday, May 11 - Your Fertility Journey and the Mind/Body Connection
presented by Alice Domar, PhD, author of "Conquering Infertility" and
Director of the Mind/Body Center for Women's Health at Boston IVF
-- Wednesday, May 12 - A Couple's Guide to Coping with Infertility
presented by Leila Kenzel, co-founder of FertilityLA and former actress
on "Mad About You"
"I've found that many patients benefit from getting information and
support because it helps them cope with infertility in a positive way," says
Dr. Scott. Registrants can submit questions for the experts by logging onto
http://www.seronofertility.com from now through May 9.
About Fertility LifeLines(TM)
Available toll free at 1-866-LETS-TRY (1-866-538-7879), Fertility
LifeLines(TM) is staffed with infertility nurses, customer service
representatives and reimbursement specialists who are specially trained to
respond to the needs of individual callers. Callers have access to a wide
range of resources, including questions to ask a doctor, explanations of
available tests and treatments and emotional support through compassionate
listening. The new service also helps callers identify payment options for
treatments by offering insurance coverage information and benefits
verification.
"Fertility LifeLines(TM) is a unique service that offers personal support
to individuals at every stage of the patient journey, whether they're just
beginning to learn about infertility, they're recently diagnosed or they're
undergoing treatment," said Bharat Tewarie, MD, Executive Vice President,
Reproductive Health, Serono, Inc. "Fertility LifeLines(TM) is the only
service of its kind available from a manufacturer of infertility treatment.
It's part of Serono, Inc.'s commitment to developing patient-friendly products
and services for people concerned about fertility."
Fertility LifeLines(TM) is open Monday through Friday from 8 am to
midnight EDT and Saturday and Sunday from 8 am to 6 pm EDT. For more
information, visit http://www.seronofertility.com or call toll-free 1-866-LETS-TRY
(1-866-538-7879).
About Infertility
Infertility is defined as the inability to achieve pregnancy after one
year of regular, unprotected intercourse (six months if the woman is over 35).
It affects about 6.1 million Americans, which represents about 10 percent of
couples in their childbearing years.
About Serono, Inc. and Infertility
Serono, Inc. is dedicated to providing patient-friendly, innovative
products to help couples build families. It is the only company to offer a
full portfolio of fertility drugs for every stage of the reproductive cycle
and recombinant versions of two hormones used to treat infertility.
About Serono
Serono, Inc., located in Rockland, MA, is the US affiliate of Serono, a
global biotechnology leader, headquartered in Geneva, Switzerland. Serono has
seven recombinant products, Rebif(R) (interferon beta-1a), Gonal-f(R)
(follitropin alfa for injection), Luveris(R) (lutropin alfa), Ovidrel
PreFilled Syringe(R)/Ovitrelle(R) (choriogonadotropin alfa injection),
Serostim(R) [somatropin (rDNA origin) for injection], Saizen(R) [somatropin
(rDNA origin) for injection] and Zorbtive(TM) [somatropin (rDNA origin) for
injection]. (Luveris(R) is not approved in the USA.)(1) In addition to being
the world leader in reproductive health, Serono has strong market positions in
neurology, metabolism and growth. Serono's research programs are focused on
growing these businesses and on establishing new therapeutic areas. Currently,
there are approximately 30 ongoing development projects.
In 2003, Serono achieved worldwide revenues of US$2,018.6 million, and a
net income of US$390.0 million, making it the third largest biotech company in
the world. Its products are sold in over 90 countries. Bearer shares of Serono
S.A., the holding company, are traded on the virt-x (SEO) and its American
Depositary Shares are traded on the New York Stock Exchange (SRA).
Some of the statements in this press release are forward looking. Such
statements are inherently subject to known and unknown risks, uncertainties
and other factors that may cause actual results, performance or achievements
of Serono S.A. and affiliates to be materially different from those expected
or anticipated in the forward-looking statements. Forward-looking statements
are based on Serono's current expectations and assumptions, which may be
affected by a number of factors, including those discussed in this press
release and more fully described in Serono's Annual Report on Form 20-F filed
with the U.S. Securities and Exchange Commission on March 25, 2004. These
factors include any failure or delay in Serono's ability to develop new
products, any failure to receive anticipated regulatory approvals, any
problems in commercializing current products as a result of competition or
other factors, our ability to obtain reimbursement coverage for our products,
and government regulations limiting our ability to sell our products. Serono
has no responsibility to update the forward-looking statements contained in
this press release to reflect events or circumstances occurring after the date
of this press release.
For more information, please contact:
Serono, Inc., Rockland, MA
Media Relations:
Tel. +1 781 681 2340
Fax: +1 781 681 2935
http://www.seronousa.com
(1) Package inserts for Serono's US marketed products are available at
http://www.seronousa.com or by calling 1-888-275-7376.
SOURCE Serono, Inc.
 back to top
Related links:
http://www.seronousa.com
CONTACT:
Serono, Inc., Media Relations,
+1-781-681-2340
|
